7 trends in life sciences investment this week
From 27 October 2026 to 2 November 2026, 15 biotech and health care companies reported $24.1 million of new private money in SEC Form D filings (company count down 36% on the 4-week average of 23.5), and companies registered 571 new trials, 233 of them at Phase 3.
As of . Research from public records, not investment advice.
- Venture money into biotech and health care: 15 operating companies reported Form D sales, $24.1 million in total. Companies down 36% on the 4-week average of 23.5; money down 85% on the 4-week average of $159.4 million.Source: SEC Form D
- Largest biotech or health care raise: Septal Solutions, Inc. sold $7.3 million. Other Health Care, Form D filed 27 October 2026.Source: SEC Form D
- New company-sponsored trials: 571 registered. Up 59% on the 4-week average of 360.3.Source: ClinicalTrials.gov
- New company-sponsored Phase 3 trials: 233 registered. Up 40% on the 4-week average of 166.3.Source: ClinicalTrials.gov
- Medicines stepping up a phase: 30 medicines entered a higher trial phase. Tuesday's list has the 12 largest.Source: ClinicalTrials.gov
- Disease with the most new company trials: Breast Cancer, 10 new trials.Source: ClinicalTrials.gov
- Licensing and partnership deals: 13 deals, $1.4 billion disclosed upfront. Down 31% on the 4-week average of 18.8.Source: Company filings and announcements
How this list is made
Each line compares the 7 days to yesterday with the average of the 4 weeks before; a line is left out while its source has no record for the week yet. Raises are SEC Form D sales by operating biotech, pharmaceutical and health care companies (funds and vehicles left out). Trials are registrations on ClinicalTrials.gov; approvals, clearances and warning letters come from FDA records.
Sources: SEC EDGAR, Form D, ClinicalTrials.gov, FDA.